Cargando…

PIONEER trial: favipiravir to treat moderate COVID-19

Detalles Bibliográficos
Autor principal:	Shalhoub, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750180/ https://www.ncbi.nlm.nih.gov/pubmed/36528037 http://dx.doi.org/10.1016/S2213-2600(22)00479-9

Ejemplares similares

Interferon beta-1b for COVID-19
por: Shalhoub, Sarah
Publicado: (2020)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Quantitative plasma proteome profiling of COVID-19 patients with mild and moderate symptoms
por: Jiang, He-wei, et al.
Publicado: (2021)

Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
por: Joshi, Shashank, et al.
Publicado: (2022)

Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care
por: Shah, Pallav L, et al.
Publicado: (2023)

An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
por: Sarojvisut, Phahol, et al.
Publicado: (2023)

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
por: Ciccolini, Joseph, et al.
Publicado: (2020)

Treating COVID-19-related breathlessness with novel interventions
por: Daynes, Enya
Publicado: (2022)

Combining active ingredients to treat depression in the wake of COVID-19
por: Abas, Melanie A
Publicado: (2022)

COVID-19, community trials, and inclusion
por: Gill, Paramjit S, et al.
Publicado: (2021)

Author Correction: Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

Biomarkers for cardiovascular risk prediction: from pioneering to evidence-based use in clinical practice
por: Hemels, M. E. W.
Publicado: (2022)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Efficacy and Safety of Favipiravir in Treating COVID-19 Patients: A Meta-Analysis of Randomized Control Trials
por: Batool, Saima, et al.
Publicado: (2023)

Anticoagulation in COVID-19: reaction to the ACTION trial
por: Berger, Jeffrey S, et al.
Publicado: (2021)

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Thoracic surgery in a hospital dedicated to treating COVID-19: challenges and solutions
por: Mariani, Alessandro Wasum, et al.
Publicado: (2020)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Alternatives to conventional hospitalisation that enhance health systems' capacity to treat COVID-19
por: Nicolás, David, et al.
Publicado: (2021)

Rethinking cancer clinical trials for COVID-19 and beyond
por: Doherty, Gary J., et al.
Publicado: (2020)

COVID-19: ACT trials for colchicine and antithrombotic therapies
por: Barco, Stefano, et al.
Publicado: (2022)

Stewardship of COVID-19 volunteers by nested trial design
por: Gottlieb, Robert L, et al.
Publicado: (2022)

US COVID-19 clinical trial leadership gender disparities
por: Sehgal, Neil K R, et al.
Publicado: (2023)

The COVID-19 pandemic: a catalyst to improve clinical trials
por: Gaba, Prakriti, et al.
Publicado: (2020)

COVID-19 vaccine trials should seek worthwhile efficacy
por: Krause, Philip, et al.
Publicado: (2020)

Mitigating the impacts of COVID-19: where are the mental health trials?
por: Gilbody, Simon, et al.
Publicado: (2021)

PRINCIPLE: a community-based COVID-19 platform trial
por: Macleod, John, et al.
Publicado: (2021)

Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir
por: Alosaimi, Bandar, et al.
Publicado: (2022)

Evaluation of the effect of favipiravir on patients with COVID-19
por: Kamali, Alireza, et al.
Publicado: (2023)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Clinical trials of disease stages in COVID 19: complicated and often misinterpreted
por: Park, Jay J H, et al.
Publicado: (2020)

COVID-19 vaccines: breaking record times to first-in-human trials
por: Kim, Young Chan, et al.
Publicado: (2020)

Haemoperfusion should only be used for COVID-19 in the context of randomized trials
por: Clark, Edward G., et al.
Publicado: (2020)

Challenges in operationalising clinical trials in India during the COVID-19 pandemic
por: Bassi, Abhinav, et al.
Publicado: (2022)

Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential
por: Krause, Philip R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oi59sjcdb2fob3f8c5f84f27bg